BEAM लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

खरीदें 67364 min ago

@ $35.38

जारी किया गया: 21 Mar 2024 @ 23:37

वापसी: -35.61%

पिछला सिग्नल: Mar 20 - 20:45

पिछला सिग्नल: बेचें

वापसी: 1.94 %

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 01:30):

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States...

Stats
आज की मात्रा	917 244
औसत मात्रा	1.54M
बाजार मूल्य	1.86B
EPS	$0 ( 2024-02-27 )
अगली कमाई की तारीख	( $-1.450 ) 2024-05-08
Last Dividend	$0.225 ( 2014-02-04 )
Next Dividend	$0 ( N/A )
P/E	-13.24
ATR14	$0.0270 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-26	Burrell Terry-ann	Buy	12 500	Common Stock
2024-04-26	Burrell Terry-ann	Buy	25 000	Stock Option (Right to Buy)
2024-04-01	Simon Amy	Sell	7 157	Common Stock
2024-04-02	Simon Amy	Sell	16 530	Common Stock
2024-04-01	Bellon Christine	Sell	3 401	Common Stock

INSIDER POWER
-11.09
Last 98 transactions
Buy: 1 537 714 \| Sell: 1 873 404

मात्रा सहसंबंध

लंबा: -0.40 (neutral)

छोटा: 0.95 (very strong)

Signal:(53.985) Expect same movement, but be aware

Beam Therapeutics Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
TUEM	0.951
TWST	0.942
CSSE	0.929
ROST	0.927
MDRX	0.926
RKDA	0.924
AFIB	0.923
HMST	0.923
AGIO	0.922
ATSG	0.922

10 सबसे अधिक नकारात्मक सहसंबंध
WIRE	-0.933
CPTA	-0.928
TYHT	-0.928
ZGNX	-0.926
HTBI	-0.92
VC	-0.92
PAE	-0.919
SGEN	-0.919
RAM	-0.916
EBSB	-0.91

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Beam Therapeutics Inc सहसंबंध - मुद्रा/वस्त्र

0.67
( moderate )

0.65
( weak )

0.00
( neutral )

-0.47
( neutral )

-0.10
( neutral )

-0.45
( neutral )

Beam Therapeutics Inc वित्तीय

Annual	2023
राजस्व:	$377.71M
सकल लाभ:	$357.70M (94.70 %)
EPS:	$-1.720

FY	2023
राजस्व:	$377.71M
सकल लाभ:	$357.70M (94.70 %)
EPS:	$-1.720

FY	2022
राजस्व:	$60.92M
सकल लाभ:	$38.34M (62.94 %)
EPS:	$-3.76

FY	2021
राजस्व:	$51.84M
सकल लाभ:	$51.84M (100.00 %)
EPS:	$-5.77

Financial Reports:

No articles found.

Beam Therapeutics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Beam Therapeutics Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.443 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.190	2011-11-07
Last Dividend	$0.225	2014-02-04
Next Dividend	$0	N/A
Payout Date	2014-03-03
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	$2.16	--
Avg. Dividend % Per Year	0.00%	--
Score	1.6	--
Div. Sustainability Score	1.443
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.60

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.318	1.500	-6.36	-9.54	[0 - 0.5]
returnOnAssetsTTM	-0.0823	1.200	-2.74	-3.29	[0 - 0.3]
returnOnEquityTTM	-0.144	1.500	-2.71	-4.07	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	5.89	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.79	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.12	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.119	-1.500	8.02	-10.00	[0 - 0.6]
interestCoverageTTM	-5.10	1.000	-3.00	-3.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.845	2.00	-0.615	-1.230	[0 - 30]
freeCashFlowPerShareTTM	-2.26	2.00	-1.131	-2.26	[0 - 20]
debtEquityRatioTTM	0.176	-1.500	9.29	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.928	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.467	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.862	1.000	-5.90	-5.90	[0.2 - 2]
assetTurnoverTTM	0.259	0.800	-1.608	-1.287	[0.5 - 2]
Total Score				1.443

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-15.34	1.000	-1.650	0	[1 - 100]
returnOnEquityTTM	-0.144	2.50	-1.744	-4.07	[0.1 - 1.5]
freeCashFlowPerShareTTM	-2.26	2.00	-0.754	-2.26	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.845	2.00	-0.615	-1.230	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.287	1.500	-5.25	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.395	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.66

Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

के लिए वास्तविक समय के अद्यतन Beam Therapeutics Inc [BEAM]

Upcoming Earnings Alert

Beam Therapeutics Inc Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)